WallStSmart

Atara Biotherapeutics Inc (ATRA)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 402% more annual revenue ($606.42M vs $120.77M). ATRA leads profitability with a 27.1% profit margin vs -2.1%. ATRA earns a higher WallStSmart Score of 41/100 (D).

ATRA

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 6.0Value: 8.3Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATRAUndervalued (+73.7%)

Margin of Safety

+73.7%

Fair Value

$17.48

Current Price

$4.99

$12.49 discount

UndervaluedFair: $17.48Overvalued

Intrinsic value data unavailable for INSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATRA2 strengths · Avg: 9.5/10
P/E RatioValuation
1.9x10/10

Attractively priced relative to earnings

Profit MarginProfitability
27.1%9/10

Keeps 27 of every $100 in revenue as profit

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ATRA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$40.15M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-20.1%2/10

ROE of -20.1% — below average capital efficiency

Revenue GrowthGrowth
-95.1%2/10

Revenue declined 95.1%

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ATRA

The strongest argument for ATRA centers on P/E Ratio, Profit Margin. Profitability is solid with margins at 27.1% and operating margin at -3.4%.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ATRA

The primary concerns for ATRA are EPS Growth, Market Cap, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ATRA profiles as a declining stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

ATRA generates stronger free cash flow (-6M), providing more financial flexibility.

Bottom Line

ATRA scores higher overall (41/100 vs 39/100), backed by strong 27.1% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Atara Biotherapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?